175 related articles for article (PubMed ID: 21241160)
1. Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(1):87-98. PubMed ID: 21241160
[TBL] [Abstract][Full Text] [Related]
2. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.
Tina Shih YC; Xu Y; Elting LS
Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
4. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
Burke TA; Wisniewski T; Ernst FR
Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer.
Miller PJ; Balu S; Buchner D; Walker MS; Stepanski EJ; Schwartzberg LS
J Med Econ; 2013 Oct; 16(10):1179-89. PubMed ID: 23919632
[TBL] [Abstract][Full Text] [Related]
6. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.
Ihbe-Heffinger A; Ehlken B; Bernard R; Berger K; Peschel C; Eichler HG; Deuson R; Thödtmann J; Lordick F
Ann Oncol; 2004 Mar; 15(3):526-36. PubMed ID: 14998860
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
9. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
Osorio-Sanchez JA; Karapetis C; Koczwara B
Intern Med J; 2007 Apr; 37(4):247-50. PubMed ID: 17388865
[TBL] [Abstract][Full Text] [Related]
11. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial.
Dibble SL; Luce J; Cooper BA; Israel J; Cohen M; Nussey B; Rugo H
Oncol Nurs Forum; 2007 Jul; 34(4):813-20. PubMed ID: 17723973
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.
Booth CM; Clemons M; Dranitsaris G; Joy A; Young S; Callaghan W; Trudeau M; Petrella T
J Support Oncol; 2007 Sep; 5(8):374-80. PubMed ID: 17944146
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
14. The cost of chemotherapy-induced nausea and vomiting in Italy.
Ballatori E; Roila F; Ruggeri B; Porrozzi S; Iannopollo M; Soru G; Cruciani G; Daniele B; Locatelli MC; Pellissier J; Deuson R
Support Care Cancer; 2007 Jan; 15(1):31-8. PubMed ID: 16788840
[TBL] [Abstract][Full Text] [Related]
15. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.
Antonarakis ES; Hain RD
Arch Dis Child; 2004 Sep; 89(9):877-80. PubMed ID: 15321871
[TBL] [Abstract][Full Text] [Related]
16. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Aapro MS
Ariz Med; 1981 Nov; 38(11):843-5. PubMed ID: 6274276
[No Abstract] [Full Text] [Related]
17. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population.
Haiderali A; Menditto L; Good M; Teitelbaum A; Wegner J
Support Care Cancer; 2011 Jun; 19(6):843-51. PubMed ID: 20532923
[TBL] [Abstract][Full Text] [Related]
18. [Role of the hospital pharmacist in the management of chemotherapy-induced nausea and vomiting].
Breton D; Jandard V; Cauet A; Paillet M; Galvez O; Faure A; Camus G; Beltrando X; Rimlinger H; Hervouet M; Margery J; Bohand X; Vaylet F
J Pharm Belg; 2011 Jun; (2):46-50. PubMed ID: 21823442
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
Kwong WJ; Parasuraman TV
Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
[TBL] [Abstract][Full Text] [Related]
20. [An assessment tool for chemotherapy-induced nausea and vomiting and intervention outcomes].
Aimono Y; Suzuki S; Nemoto M; Saito Y; Aoyama Y; Joko F; Maruyama T; Kamoshida T
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2551-4. PubMed ID: 24335368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
